Stephane Champiat, MD

Other Articles

1. Mayrikios A, Baldini C, Loriot Y, Henon C, Marabelle A, Postel-Vinay, Champiat S, Danlos FX, Quevrin C, Lopes E, Gazzah A, Bahleda R, Massard C, Deutsch E, Levy A Is local ablative stereotactic radiation therapy a valuable rescue strategy for time on drug in patients enrolled in phase I trials?. Int J Radiat Oncol Biol Phys S0360-3016(24):03207-3, 2024. PMID: None.
2. Mathiot L, Baldini C, Letissier O, Hollebecque A, Bahleda R, Gazzah A, Smolenschi C, Sakkal M, Danlos FX, Henon C, Beshiri K, Goldschmidt V, Parisi C, Patrikidou A, Michot JM, Marabelle A, Postel-Vinay S, Bernard-Tessier A, Loriot Y, Ponce S, Champiat S, Ouali K Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review. Curr Oncol Rep None(None):None, 2024. PMID: None.
3. Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgraber V, Morena V Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer. Clin Cancer Res None(None):None, 2024. PMID: None.
4. Geraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauguil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Olivier L, Massard C, Marabelle A, Castilla-Llorenta C, Champiat S, Michot JM Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer 205(None):114075, 2024. PMID: None.
5. Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, Michot JM, M Ribeiro J, Scotte F, Ponce Aix S, Lambotte O, Baldini C, Champiat S Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations. Cancer Treat Rev 127(None):102751, 2024. PMID: None.
6. Mathiot L, Combarel D, Cagnat J, Delahousse J, Ouali K, Marabelle A, Loriot Y, Ponce S, Champiat S, Broutin D, Danlos FX Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. J Immunother Cancer 12(5):e008847, 2024. PMID: None.
7. Rodriguez J, Baldini C, Bayle A, Pages A, Danlos FX, Vasseur D, Rouleau E, Lacroix L, Alonso de Castro B, Goldschmidt V, Seknazi L, Hollebecque A, Michot JM, Champiat S, Marabelle A, Ouali K, Marzac C, Ponce S, Micol JB, Chaput N, Massard C, Italiano A Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial. JCO Precis Oncol None(None):e2300631, 2024. PMID: None.
8. Pourmir I, Nebbache R, Champiat S, Lambotte O, Cancer Immunotherapy Adverse Events Working Group Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?. Ann Oncol S0923-7534(24):00083-8, 2024. PMID: None.
9. Rached L, Geraud A, Frelaut M, Ap Thomas Z, Goldschmidt V, Beraud-Chaulet G, Nagera-Lazarovici C, Danlos FX, Henon C, Parisi C, Gazzah A, Bahleda R, Postel Vinay S, Smolenschi C, Hollebecque A, Michot JM, Ribrag V, Loriot Y, Champiat S, Ouali K, Massard C, Ponce Aix S, Bringuier M, Baldini C Antibody drug conjugates in older patients: State of the art. Crit Rev Oncol Hematol 193(None):104212, 2024. PMID: None.
10. Alouani E, Laparra A, Perret A, Sakkal M, Messayke S, Danlos FX, Ouali K, Hollebecque A, Even C, Ammari S, Baldini C, Champiat S, Besse B, Robert C, Guettier C, Samuel D, Lambotte O, De Martin E, Michot JM Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. Eur J Cancer 113313(None):None, 2023. PMID: None.
11. Boucher R, Haigh O, Barraeu E, Champiat S, Lambotte O, Adam C, Labetoulle M, Rousseau A Ocular surface toxicities associated with modern anticancer therapies. Surv Ophthalmol S0039-6257(23):00134-0, 2023. PMID: None.
12. Valery M, Saleh K, Ecea R, Michot JM, Ribrag V, Fizazi K, Hollebecque A, Lecesne A, Ponce S, Loriot Y, Champiat S, Baldini C, Sarkozy C, Castilla-Llorente C Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients. Cancer Chemother Pharmacol 92(3):229-233, 2023. PMID: None.
13. Ghosn M, Tselikas L, Champiat S, Deschamps F, Bonnet B, Carre E, Testan M, Danlos FX, Farhane S, Susini S, Suzzoni S, Ammari S, Marabelle A, De Baere T Intratumoral Immunotherapy: Is It Ready for Prime Time?. Curr Oncol Rep 25(8):857-867, 2023. PMID: None.
14. Alouani E, Gazzah A, Mercier S, Bahleda R, Hollebecque A, Michot JM, Baldini C, Ammari S, Champiat S, Marabelle A, Postel-Vinay S, Ribrag V, Loriot Y, Aix SP, Mahjoubi L Profile and outcome of cancer patients enrolled in contemporary phase I trials. Eur J Cancer 188(None):1-7, 2023. PMID: None.
15. Champiat S, Salaun H, Lucibello F, Scoazec JY, Besse B, Lalanne AI, Rouleau E, Metzger N, Saint-Ghislain M, Ryckewaert T, Gardrat S, Barnhill R, Cassoux N, Stern MH, Lantz O, de Koning L, Marabelle A, Rodrigues M Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma. JCO Precis Oncol 7(None):e2200363, 2023. PMID: None.
16. Belkouchi Y, Talbot H, Lassau N, Lawrence L, Farhane S, Feki-Mkaouar R, Hadchiti J, Dawi L, Vibert J, Cournede PH, Cousteix C, Mazza C, Kind M, Italiano A, Marabelle A, Ammari S, Champiat S Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy. Clin Cancer Res 29(8):1528-1534, 2023. PMID: None.
17. Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer 11(3):e005301, 2023. PMID: None.
18. Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, Krug LM, Moslehi J, Pietanza MC, Riemer J, Robert C, Sharon E, Suarez-Almazor ME, Suresh K, Turner M, Weber J, Cappelli LC Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer 11(3):e006398, 2023. PMID: None.
19. Champiat S, Marabelle A Paradoxical cancer cell stimulation by IFNγ drives tumor hyperprogression upon checkpoint blockade immunotherapy. Cancer Cell 41(2):229-231, 2023. PMID: None.
20. Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Sadraei NH, Owonikoko TK Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. J Clin Oncol 23(None):101200JCO2202823, 2023. PMID: None.
21. Veley M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, Teysseire S, Danlos FX, Albiges L, Bernigaud C, Benderra MA, Pradere P, Zaidan M, Decroisette C, Fallah F, Matergia G, Layaud P, Jantzem H, Atzenhoffer M, Buyse V, Ammari S, Robert C, Champiat S, Messayke S, Marabelle A, Guettier C, Lebbe C, Lambotte O, Michot JM Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. Eur J Cancer 179(None):28-47, 2023. PMID: None.
22. Danlos FX, Texier M, Job B, Mouraud S, Cassard L, Baldini C, Varga A, Yurchenko AA, Rabeau A, Champiat S, Letourneur D, Bredel D, Susini S, Blum Y, Parpaleix A, Parlavecchio C, Tselikas L, Fahrner JE, Goubet AG, Rouanne M, Rafie S, Abbassi A, Kasraoui I, Breckler M, Farhane S, Ammari S, Laghouati S, Gazzah A, Lacroix L, Besse B, Droin N, Deloger M, Cotteret S, Adam J, Zityogel L, Nikolaev SI, Chaput N, Massard C, Soria JC, Gomez-Roca C, Zalcman G, Planchard D, Marabelle A Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma. Cancer Discov 20(None):CD-22-0886, 2023. PMID: None.
23. Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, Texier M Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treat Rev 110(None):102452, 2022. PMID: None.
24. Antoun S, Lanoy E, Ammari S, Farhane S, Martin L, Robert C, Champiat S, Planchard D, Routier E, Voisin AL, Messayke S, Michot JM, Laghouati S, Lambotte O, Marabelle A, Baracos V Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. Eur J Cancer 178(None):49-59, 2022. PMID: None.
25. Hilmi M, Naoun N, Boileve A, Geraud A, Bayle A, Pages A, Aupomerol M, Rouanne M, Madec FX, Pommeret F, Massard C, Baldini C, Scotte F, Champiat S Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study. Support Care Cancer None(None):None, 2022. PMID: None.
26. Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, Besse B, Planchard D, Hollebeccque A, Champiat S, Marabelle A, Michot JM, Massard C, Mezquita L Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers (Basel) 14(20):5078, 2022. PMID: None.
27. Dercle L, Ammari S, Roblin E, Beigorgne A, Champiat S, Taihi L, Plaian A, Hans S, Lakiss S, Tselikas L, Rouanne M, Duetsch E, Schwartz LH, Gonen M, Flynn J, Massard C, Soria JC, Robert C, Marabelle A High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. Eur J Cancer 177(None):80-93, 2022. PMID: None.
28. Jost R, Al-Shatti N, Ghosn M, Bonnet B, Champiat S, Deschamps F, Gelli M, Boige V, Danlos FX, Susini S, Hollebecque A, Ammari S, Marabelle A, de Baere T, Tselikas L Synergizing liver systemic treatments with interventional oncology: friend or foe?. Br J Radiol 95(1138):20220548, 2022. PMID: None.
29. Ollivier L, Orione C, Bore P, Misery L, Legoupil D, Leclere JC, Coste A, Girault G, Sicard-Cras I, Kacperek C, Lucia F, Stefan D, Thillays F, Rio E, Lesueur P, Berthou C, Heymann D, Champiat S, Supiot S, Vaugier L, Kao W Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study. Cancers (Basel) 14(17):4213, 2022. PMID: None.
30. Ouali K, Mateus C, Laparra A, Martin Romano P, Sampetrean A, Vaugnat P, Varga A, Champiat S, Verlingue L, Geraud A, Marabelle A, Hollebecque A, Gazzah A, Bahleda R, Postel Vinay S, Michot JM, Bernard-Tessier A, Bayle A, Ribrag V, Soria JC, Scotte F, Massard C, Pavliuc E, Baldini C PALLIA 10 score in phase I cancer studies. BMJ Support Palliat Care 30(None):bmjspcare-2022-003601, 2022. PMID: None.
31. Martin-Romano P, Colmet-Daage L, Morel D, Baldini C, Verlingue L, Bahleda R, Gazzah A, Champiat S, Varga A, Michot JM, Ngo-Camus M, Nicotra C, Marabelle A, Soria JC, Rouleau E, Lacrois L, Hollebecque A, Massard C, Postel-Vinay S Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. Eur J Cancer 173(None):133-145, 2022. PMID: None.
32. Lambert T, Pobel C, Colmet-Daage L, Bigorgne A, Rauby B, Aladro NS, Ter-Minassian L, Kerisit M, Marabelle A, Besse B, Hollebeque A, Champiat S, Massard C, Morel D, Velringue L, Scoazec JY Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. Cancer Treat Res Commun 32(None):100611, 2022. PMID: None.
33. Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zityogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. J Exp Clin Cancer Res 41(1):217, 2022. PMID: None.
34. Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Expert Rev Anticancer Ther 14(None):1-12, 2022. PMID: None.
35. Tselikas L, Dardenne A, de Baere T, Faron M, Ammari S, Farhane S, Suzzoni S, Danlos FX, Raoult T, Susini S, Al Shatti N, Mouraud S, Deschamps F, Kobe A, Delpla A, Roux C, Baldini C, Soria JC, Barlesi F, Massard C, Robert C, Champiat S, Marabelle A Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. Eur J Cancer 172(None):1-12, 2022. PMID: None.
36. Rousseau B, Bieche I, Pasmant D, Hamzaoui N, Leulliot N, Michon L, de Reynies A, Attignon V, Foote MB, Masliah-Planchon J, Syrcek M, Cohen R, Simmet V, Augereau P, Malka D, Hollebecque A, Pouessel D, Gomez-Roca C, Guimbaud R, Bruyas A, Guillet M, Grob JJ, Duluc M, Cousin S, de la Fouchardiere C, Flechon A, Rolland F, Hiret S, Saada-Bouzid E, Bouche O, Andre T, Pannier D, El Haibi F, Oudard S, Tournigand C, Soria JC, Champiat S, Gerber DG, Stephens D, Lamendola-Essel MF, Maron SB, Diplas BH, Argiles G, Krishnan AR, Tabone-Eglinger S, Ferrari A, Segal NH, Cercek A, Hoog-Labouret N, Legrand F, Simon C, Lamrani-Ghaouti A, Diaz LA, Saintigny P, Chevret S, Marabelle A PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discov 12(6):1435-1448, 2022. PMID: None.
37. Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Luis Perez Gracia J, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Ruttinger D, Delord JP, Marabelle A Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunother Cancer 10(5):e004076, 2022. PMID: None.
38. Bonvalet M, Danlos FX, Champiat S, Rouanne M, Marabelle A Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals. Eur J Cancer 162(None):130-132, 2022. PMID: None.
39. Martin-Romano P, Adam J, Scoazec JY, Gouy S, Levy A, Baldini C, Champiat S, Soria JC, Massard C, Marabelle A, Deutsch E, Hollebecque A Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?. Front Immunol 12(None):745146, 2021. PMID: None.
40. Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Eur J Cancer 158(None):217-224, 2021. PMID: None.
41. Panhaleux M, Espitia O, Terrier B, Manson G, Maria A, Humbert S, Godbert B, Perrin J, Achille A, Arrondeau J, Kostine M, Fallet V, Pugnet G, Chaigne B, Champiat S, Laparra A, Danlos FX, Launay D, Penel N, Lambotte O, Michot JM, Forestier A Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. Eur J Cancer 19(None):S0959-8049(21)01176-X, 2021. PMID: None.
42. Hajem S, Ederhy S, Champiat S, Troalen F, Nolin-Lapalme A, Berhoune M, Cauquil C, Martin-Romano P, Baldini C, Laparra A, Vuagnat P, Hollebecque A, Mateus C, Besse B, Naltet C, Robert C, Marabelle A, Massard C, Lambotte O, Michot JM Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. Eur J Cancer 157(None):383-390, 2021. PMID: None.
43. Addou S, Sarkozy C, Lazarovici J, Champiat S, Stanatoullas A, Jardin F, Ribrag V, Marabelle A, Michot JM Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?. Hum Vaccin Immunother 17(10):3502-3510, 2021. PMID: None.
44. Placais L, Michot JM, Champiat S, Romano-Martin P, Baldini C, Joao MS, Marabelle A, Voisin AL, Not A, Labeyrie C, Beaudonnet G, Laparra A, Maria ATJ, Masseau A, Dehette S, Deleporte A, Echanis-Laguna A, Denier C, Adams D, Lambotte O, Noel N, Caiguil C Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun 3(4):fcab220, 2021. PMID: None.
45. Cabanie C, Ammari A, Hans S, Pobel C, Laparra A, Danlos FX, Chanson N, Dolidon S, Seban R, Voisin AL, Pautier P, Romano-Martin P, Even C, Baldini C, Besse B, Albiges L, Boutros C, Routier E, Balleyguier C, De Montpreville VT, Champiat S, Massard C, Robert C, Marabelle A, Mateus C, Lambotte O, Le Pavec J, Michot JM Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. Eur J Cancer 156(None):46-59, 2021. PMID: None.
46. Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 18(9):558-576, 2021. PMID: None.
47. Roulleaux Dugage M, Jones RL, Trent J, Champiat S, Dumont S Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Front Immunol 12(None):715727, 2021. PMID: None.
48. Bayle A, Baldini C, Martin-Romano P, Michot JM, Champiat S, Bahleda R, Gazzah A, Marabelle A, Verlingue L, Geraud A, Morel D, Michiels S, Hollebecque A, Albiges L, Besse B, Soria JC, Massard C, Barlesi F, Postel-Vinay S Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell 39(8):1039-1041, 2021. PMID: None.
49. Ederhy S, Salem JE, Dercle L, Hansan AS, Chauvet-Droit M, Nhan P, Ammari S, Pinna B, Redheuil A, Boussouar S, Champiat S, Soulat-Dufour L, Cohen A Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. Front Oncol 11(None):640985, 2021. PMID: None.
50. Izzedine H, Mathian A, Albiges L, Champiat S, Brocheriou I Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients. Eur J Cancer 149(None):34-36, 2021. PMID: None.
51. Laparra A, Kfoury M, Champiat S, Danlos FX, Martin-Romano P, Simonaggio A, Baldini C, Vuagnat P, Mateus C, Voisin AL, Albiges L, Besse B, Even C, Robert C, Laghouati S, Massard C, Marabelle A, Lambotte O, Michot JM Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. Ann Oncol S0923-7534(21):01143-1, 2021. PMID: None.
52. Champiat S, Tselikas L, Farhane S, Raoult T, Texier M, Lanoy E, Massard C, Robert C, Ammari A, de Baere T, Marabelle A Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clin Cancer Res 27(3):665-679, 2021. PMID: None.
53. Tselikas L, Champiat S, Sheth RA, Yevich S, Ammari A, Deschamps F, Farhane S, Roux C, Susini S, Mouraud S, Delpla A, Raoult T, Robert C, Massard C, Barlesi F, Soria JC, Marabelle A, de Baere T Interventional Radiology for Local Immunotherapy in Oncology. Clin Cancer Res None(None):None, 2021. PMID: None.
54. Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C, Ammari S Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother 70(1):221-232, 2021. PMID: None.
55. Curty G, Beckerle GA, Iniguez LP, Furler RL, de Carvalho PS, Marston JL, Champiat S, Heymann JJ, Ormsby CE, Reyes-Teran G, Soares MA, Nixon DF, Bendhall ML, Leal FE, de Mulder Rougvie M Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study. Front Oncol 10(None):553983, 2020. PMID: None.
56. Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, Cohen-Solal A, Cohen A, Dolladille C, Thuny F Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 9(18):e018403, 2020. PMID: None.
57. Martin-Romano P, Ammari S, El-Dakdoukti Y, Baldini C, Varga A, Vuagnat P, Angevin E, Bahleda R, Gazzah A, Champiat S, Michot JM, Postel-Vinay S, Marabelle A, Soria JC, Boige V, Malka D, Ducreux M, Massard C, Hollebecque A Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer 137(None):117-126, 2020. PMID: None.
58. Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O Letter responds to the comment in 'immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty'. Eur J Cancer 134(None):60-61, 2020. PMID: None.
59. Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, Danlos FX, Ammari S, Cauguil C, Ederhy S, Barreau E, Belkhir R, Berdelou A, Lazarovici J, Chanson P, Izzedine H, Seferian A, Le Pajolec C, Baldini C, Martin-Romano P, Mariette X, Robert C, Besse B, Hollebecque A, Varga A, Laghouati S, Mateus C, Voisin AL, Soria JC, Massard C, Marabelle A, Champiat S, Lambotte O The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. Eur J Cancer 130(None):39-50, 2020. PMID: None.
60. Baldini C, Martin-Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Eur J Cancer 129(None):71-79, 2020. PMID: None.
61. Grecea M, Marabelle A, Ammari S, Massard C, Champiat S Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. Oncologist None(None):None, 2020. PMID: None.
62. Martin-Romano P, Castanon E, Ammari S, Champiat S, Hollebecque A, Postel-Vinay S, Baldini C, Varga A, Michot JM, Vuagnat P, Marabelle A, Soria JC, Ferte C, Massard C Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. None None(None):None, 2020. PMID: None.
63. Houot R, Marabelle A, Champiat S Hyperprogression upon immunotherapy: A chance for (hyper-)progress. Eur J Cancer 126(None):139-140, 2020. PMID: None.
64. Aspeslagh S, Chabanon RM, Champiat S, Postel-Vinay S Understanding genetic determinants of resistance to immune checkpoint blockers. Semin Cancer Biol S1044-579X(19):30420-1, 2019. PMID: None.
65. Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. Eur J Cancer 122(None):72-90, 2019. PMID: None.
66. Mekki A, Dercle L, Lichtenstein P, Nasser G, Marabelle A, Champiat S, Chouzenoux E, Balleyguier C, Ammari S Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer 119(None):44-56, 2019. PMID: None.
67. Champiat S, Besse B, Marabelle A Hyperprogression during immunotherapy: do we really want to know?. Ann Oncol 30(7):1028-1031, 2019. PMID: None.
68. Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL, Danlos FX, Dakdouki YE, Annereau M, Mariette X, Robert C, Cherif K, Marabelle A, Mateus C, Lambotte O Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 78(7):e67, 2019. PMID: None.
69. Simonaggio A, Michot JM, Voisin AL, LE Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol None(None):None, 2019. PMID: None.
70. Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, Voisin AL, Mateus C, Remond AL, Couret C, Champiat S, Labetoulle M, Rosseau A Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. Am J Ophthalmol 202(None):109-117, 2019. PMID: None.
71. Baldini C, Champiat S, Vuagnat P, Massard C Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential. Onco Targets Ther 12(None):2505-2512, 2019. PMID: None.
72. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C Novel patterns of response under immunotherapy. Ann Oncol 30(3):385-396, 2019. PMID: None.
73. Ferrara R, Caramella C, Besse B, Champiat S Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. J Thorac Oncol 14(3):328-331, 2019. PMID: None.
74. Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel_vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res 25(3):946-956, 2019. PMID: None.
75. Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, Michot JM, Marabelle A, Lambotte O, Amoura Z, Soria JC, Kaaki S, Quellard N, Goujon JM, Brocheriou I Renal toxicities associated with pembrolizumab. Clin Kidney J 12(1):81-88, 2019. PMID: None.
76. Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saiag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albiges L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48-e57, 2019. PMID: None.
77. Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferte C Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15(12):748-762, 2018. PMID: None.
78. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferte C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol 4(11):1543-1552, 2018. PMID: None.
79. Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferte C A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19(9):1180-1191, 2018. PMID: None.
80. Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer 101(None):160-164, 2018. PMID: None.
81. Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96(None):91-104, 2018. PMID: None.
82. Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect 24(3):216-218, 2018. PMID: None.
83. Danlos FX, Voisin AL, Dyeyre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dallas D, Besse B, Laghouati S, Soria JC, Matues C, Robert C, Lanoy E, Marabelle A, Lambotte O Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91(None):21-29, 2018. PMID: None.
84. De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol S0168-8278(18):30083-7, 2018. PMID: None.
85. Michot JM, Pruvost R, Mateus C, Champiat S, Voisin AL, Marabelle A, Lambotte O Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. Ann Oncol 29(2):518-520, 2018. PMID: None.
86. Michot JM, Ragou P, Carbonnel F, Champiat S, Voisin AL, Mateus C, Lambotte O, Annereau M Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication. J Immunother 41(2):84-85, 2018. PMID: None.
87. Louvel G, Bahleda R, Ammari S, Le Pechoux C, Levy A, Massard C, Le Pavec J, Champiat S, Deutsch E Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?. Eur Respir J 51(1):None, 2018. PMID: None.
88. Sun R, Danlos FX, Ammari S, Louvel G, Dhermain F, Champiat S, Lambotte O, Deutsch E Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?. J Immunother Cancer 5(1):96, 2017. PMID: None.
89. Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 28(11):2860-2865, 2017. PMID: None.
90. Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Caput D, Kannouche PL Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Eur J Cancer 84(None):290-303, 2017. PMID: None.
91. Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferte C Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer 84(None):202-211, 2017. PMID: None.
92. Bernard-Tessier A, Jeanville P, Champiat S, Lazarovici J, Voisin AL, Mateus C, Lambotte O, Annereau M, Michot JM Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer 81(None):135-137, 2017. PMID: None.
93. Michot JM, Vargaftig J, Leduc C, Quere G, Burroni B, Lazarovici J, Champiat S, Ribrag V, Lambotte Immune-related bone marrow failure following anti-PD1 therapy. Eur J Cancer 80(None):1-4, 2017. PMID: None.
94. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mekinian A, Coutte L, Swebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer 82(None):34-44, 2017. PMID: None.
95. Pradere P, Michot JM, Champiat S, Danlos FX, Marabelle A, Lambotte O, Albiges L, Le Pavec J Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. Eur J Cancer 75(None):308-309, 2017. PMID: None.
96. Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis None(None):None, 2017. PMID: None.
97. Ederhy S, Voisin AL, Champiat S Myocarditis with Immune Checkpoint Blockade. N Engl J Med 376(3):290-1, 2017. PMID: None.
98. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont AM, Marabelle A, Soria JC, Ferte C Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res None(None):None, 2016. PMID: None.
99. Helissey C, Vicier C, Champiat S The development of immunotherapy in older adults: New treatments, new toxicities?. J Geriatr Oncol 7(5):325-33, 2016. PMID: None.
100. Dercle L, Ammari S, Champiat S, Massard C, Ferte C, Taihi L, Steban RD, Aspeslagh S, Mahjoubi L, Lamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. Eur J Cancer 65(None):33-42, 2016. PMID: None.
101. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473-86, 2016. PMID: None.
102. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauguil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, Francois H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559-74, 2016. PMID: None.
103. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54(None):139-48, 2016. PMID: None.
104. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, Tomasic G, Soria JC, Champiat S, Texier M, Lanoy E, Robert C Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol 152(1):45-51, 2016. PMID: None.
105. Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 9(2):144-53, 2014. PMID: None.
106. Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria JC Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 3(1):e27817, 2014. PMID: None.
107. Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenburg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques. J Virol 87(11):6073-80, 2013. PMID: None.
108. Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection. PLoS One 7(6):e39311, 2012. PMID: None.
109. Garrison KE, Champiat S, York VA, Agrawal AT, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses. Clin Vaccine Immunol 16(9):1369-71, 2009. PMID: None.

Book Chapters

1. Champiat S, Michels J, Eggermont A. Blocage des rétrocontrôles inhibiteurs. In: Immunothérapie des cancers au troisième millénaire. None. EDP Sciences, None, 2015.

Books (edited and written)

1. Champiat S, Noël N. Immunoterapias. Ed(s) None. Amat Editorial, 2024.
2. Champiat S, Noël N. Immunothérapies. Ed(s) None. Guy Trédaniel Editeur, 2019.